AndrewJasonBarkerDO

PubMed

• 32 citations
  The Discovery of Azd5597, a Potent Imidazole Pyrimidine Amide Cdk Inhibitor Suitable for Intravenous Dosing.
  Clifford David Jones, David M. Andrews, Barker Andrew John, Kevin Blades, Paula Daunt, S J East, Catherine Geh, Mark A. Graham, Keith M. Johnson, Sarah A. Loddick, Hea...> ;Bioorganic & Medicinal Chemistry Letters. 2008 Dec 15
• 22 citations
  Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
  Clifford David Jones, David M. Andrews, Barker Andrew John, Kevin Blades, Kate Byth, M. Raymond V. Finlay, Catherine Geh, Clive Green, Marie Willaing Johannsen, Michae...> ;Bioorganic & Medicinal Chemistry Letters. 2008 Dec 15
• 21 citations
  Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode
  M. Raymond V. Finlay, David G. Acton, David M. Andrews, Barker Andrew John, Michael Dennis, Eric Fisher, Mark A. Graham, Clive Green, David William AstraZeneca R D Ald...> ;Bioorganic & Medicinal Chemistry Letters. 2008 Aug 1
• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
  Wakeling, A.E., Guy, S.P., Woodburn, J.R., Ashton, S.E., Curry, B.J., Barker, A.J., Gibson, K.H.> ;Cancer Res. 2002 Oct 15
• 378 citations
  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatm...
  Barker Andrew John, Keith Hopkinson Gibson, Walter Grundy, Godfrey Andrew Aydon, Jeffrey J Barlow, Mark P Healy, J. R. Woodburn, Susan Ashton, Brenda Curry, Lynn Scarl...> ;Bioorganic & Medicinal Chemistry Letters. 2001 Jul 23
• Join now to see all